Xstrahl Medical are please to present the first in a series of posts that will share the important views and work from a number of our users.
Dr John Glees using the Xstrahl 150 for treatment of Dupuytren’s disease and superficial skin cancers
The Xstrahl 150 is perfectly suited to treating a range of superficial and benign conditions thanks to its versatile design offering both orthovoltage and superficial treatment techniques in one system. Dr John Glees takes advantage of the system’s adaptability to treat a range of non-melanoma skin cancers and dermatological conditions such as Dupuytren’s and Ledderhose.
Dr John Glees
Having devoted his career to the study of radiology, working for over 40 years in the treatment of cancers and benign conditions all over the world, consultant radiotherapist and clinical oncologist Dr John Glees returned to the UK. Upon setting up his private practice he jumped at the chance to get an Xstrahl 150 radiotherapy treatment system following his past work with the Royal Marsden Hospital and St George’s University Hospital, where he jointly wrote the protocols for skin cancer.
Running his private practice at the Lister Hospital in London and working at the Cancer Centre London he now offers the most up to date radiotherapy techniques using the Xstrahl 150 to treat a range of conditions.
Dupuytren’s & Ledderhose
Dupuytren’s contracture is incredibly common, with rates in England of 20% of the population over the age of 65 having the disease. Causing a debilitating curling of fingers, the most common treatment is surgery, causing a long term and painful recovery.
However using the Xstrahl 150 Dr Glees treats many patients using radiotherapy. Once the areas to be treated are identified, calculations are done by physicists, before the radiographers treat the areas. The treatment plan usually consists of a daily visit to the treatment centre for a 5 minute treatment for a week, followed by the same course 2 months later. The applicator is pressed gently onto the hand, giving the patient no pain, and importantly, a short and problem free recovery period.
With new developments in radiotherapy and backing from positive research, and the UK National Institute for Health and Care Excellence approving and publishing guidelines in late 2010, the new painless treatment has seen a rise in use, with a 95% success rate1.
Unfortunately Dr Glees often sees 10-15% of Dupruytren’s patients suffering from an underlying Ledderhose disease as well. This non-malignant collagen growth disorder affecting the arch of the feet can cause extremely tender and painful nodules and thickening of deep connective tissues. With a similar treatment plan, Dr Glees has seen a 94% success rate where patients have said they are very pleased with the outcome.
Superficial Skin Cancers
Thanks to the Xstrahl 150’s adaptable design, treatment options for superficial non-melanoma skin cancers are also possible. Dr Glees takes advantage of this to treat many skin cancers resulting from high sun exposure in earlier life.
With unsightly scarring and long recovering times, treatment on the face, ears and neck are perfectly placed for treatment using superficial radiotherapy where treatment results in no adverse physical effects.
In addition, using a low energy x-ray radiotherapy design, the Xstrahl 150 offers a far safer option than megavoltage radiation treatments.
The Xstrahl 150’s range of energy levels makes it an ideal addition to any busy radiotherapy department. Ideal for treating many superficial skin cancers, it can also be used to treat dermatological conditions such as psoriasis, and a range of other benign conditions such as Dupuytren’s Contracture, Peyronie’s Disease and heterotopic ossification.
With the Xstrahl 150’s unique and versatile design, Dr Glees continues to treat using radiotherapies. Recently Dr Glees has even taken the system to the RAD society, a world regarded association of consultant radiotherapists, to show off the benefits of using a safe, effective treatment system for their patients.